Study: GLP-1RA not associated with acute kidney injury risk during anti-cancer treatments

Among 14,783 patients, 9% were treated with a GLP-1RA while taking ant-cancer drugs. AKI occurred in 7.2% of those exposed to GLP-1RA versus 6.4% of those with no GLP-1RA exposure.

Study: "Exposure to Glucagon Like Peptide 1 Receptor Agonists (GLP-1RA) Does Not Increase the Risk of AKI Associated with Anti-Cancer Therapy"

Source:

American Society of Nephrology